Fasting Triglycerides: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

Why Fasting Matters for Triglyceride Testing

Fasting before a triglyceride draw is non-negotiable for clinical interpretation. A meal rich in fat raises circulating chylomicrons for four to six hours, inflating the result by 20 to 70 mg/dL depending on fat load. The standard recommendation from the National Lipid Association is a 9-to-12-hour fast, water permitted, before blood is collected.

What "Fasting" Actually Means

Coffee without cream or sugar does not meaningfully alter fasting triglycerides in most adults. Alcohol the night before a draw is a different matter: a single evening of moderate drinking can raise next-morning triglycerides by 50% or more through transient hepatic VLDL overproduction. Patients on testosterone or estrogen therapy should schedule their draw at the same time of day relative to their dose, because peak hormone concentrations shift lipid kinetics within hours.

Non-Fasting vs. Fasting Panels

Some cardiovascular risk calculators now accept non-fasting triglycerides, and the European Atherosclerosis Society acknowledges that a non-fasting value below 175 mg/dL is broadly reassuring. However, for metabolic syndrome classification, MASLD staging, and titration of GLP-1 or fibrate therapy, a properly fasted sample remains the required standard. The 2019 AHA/ACC guideline on cardiovascular risk reduction explicitly uses fasting triglycerides for borderline-risk decision-making. [1]

Normal Range vs. Optimal Range: A Clinical Distinction

The "normal" range printed on a standard lab report is not the same as the level associated with lowest cardiovascular and metabolic risk. This is a gap that matters clinically.

Guideline Thresholds

The 2018 AHA/ACC Cholesterol Guideline classifies fasting triglycerides as follows [2]:

| Category | Fasting TG (mg/dL) | |---|---| | Normal | <150 | | Borderline high | 150 to 199 | | High | 200 to 499 | | Very high | 500 or above |

A value below 150 mg/dL clears the guideline threshold, but that does not mean 148 mg/dL and 72 mg/dL carry equal risk.

The Optimal Target

Longevity medicine and lipidology increasingly distinguish "normal" from "optimal." A 2022 analysis of the UK Biobank (N=117,936) found that fasting triglycerides above 100 mg/dL were independently associated with incident cardiovascular events even after LDL-C adjustment, with the lowest event rates concentrated below 80 to 100 mg/dL. The National Cholesterol Education Program (NCEP) ATP-III report identifies 150 mg/dL as the metabolic syndrome criterion, but notes that progressively lower levels track with progressively lower VLDL burden [3]. In clinical practice, a target below 100 mg/dL is the standard used by many lipid specialists and longevity physicians for patients at elevated cardiometabolic risk.

When to Treat

Pharmacologic treatment is generally initiated when fasting triglycerides exceed 500 mg/dL to reduce pancreatitis risk, using fenofibrate 145 mg/day or icosapentaenoic acid (EPA) 4 g/day. The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid 4 g/day reduced major adverse cardiovascular events by 25% in patients with baseline fasting triglycerides of 135 to 499 mg/dL on statin therapy, independent of the triglyceride-lowering effect alone [4].

Sex Differences in Fasting Triglycerides

Men and women show consistently different fasting triglyceride distributions, and those differences are driven substantially by sex hormones rather than body composition alone.

Premenopausal Advantage

Premenopausal women have lower fasting triglycerides than age-matched men. Data from the NHANES 2015 to 2018 cycle show median fasting triglycerides of approximately 88 mg/dL in women aged 20 to 39 vs. 112 mg/dL in men of the same age group [5]. Endogenous estradiol is the primary driver: it accelerates hepatic clearance of triglyceride-rich lipoproteins (VLDL and IDL) via upregulation of lipoprotein lipase (LPL) and hepatic lipase. The net effect in a cycling woman with normal estrogen is a lower fasting TG than her male counterpart at the same BMI and dietary fat intake.

The Testosterone Effect in Men

Testosterone suppresses hepatic VLDL production and increases LPL activity in adipose tissue, lowering fasting triglycerides when T is in range. A 2016 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) pooled data from 1,549 men and found that testosterone therapy reduced fasting triglycerides by a mean of 21.7 mg/dL compared to placebo, with the largest effects in hypogonadal men who had baseline triglycerides above 150 mg/dL [6]. Men with untreated hypogonadism frequently present with borderline-high or high fasting triglycerides as part of their metabolic profile.

Post-Menopause Reversal

After menopause, the female advantage disappears. Women's fasting triglycerides rise by an average of 10 to 15 mg/dL in the first two years after the final menstrual period, driven by the withdrawal of estradiol's lipase-upregulating effect and a shift toward more atherogenic VLDL particle distribution. By age 60 to 69, NHANES data show women's median fasting TG (approximately 120 mg/dL) converging with or slightly exceeding men's [5]. This is a key reason why cardiovascular risk in women accelerates post-menopause.

Menstrual Cycle Phase and Fasting Triglycerides

The menstrual cycle produces clinically meaningful within-person variation in fasting triglycerides. Failing to account for cycle phase can lead to misclassification or unnecessary repeat testing.

Follicular Phase (Days 1 to 14)

During the follicular phase, rising estradiol progressively increases LPL activity and hepatic triglyceride clearance. Fasting triglycerides are typically at their cycle-low during the late follicular phase, coinciding with the estradiol surge just before ovulation. A 1998 study by Barclay et al. In Clinical Chemistry tracked daily fasting triglycerides across 28 days in 12 healthy women and documented a 28% difference between cycle nadir and cycle peak [7].

Ovulatory Spike

At ovulation, the brief LH surge and accompanying progesterone rise produce a transient 10 to 15% uptick in fasting triglycerides. This spike lasts 24 to 48 hours. It is not clinically significant on its own, but a blood draw timed to ovulation could push a borderline-normal result into borderline-high territory.

Luteal Phase (Days 15 to 28)

Progesterone dominates the luteal phase. Progesterone partly opposes estradiol's LPL-upregulation, allowing hepatic VLDL secretion to rise. Fasting triglycerides in the mid-to-late luteal phase are typically 15 to 25% above the follicular-phase baseline in the same woman. A patient whose fasting TG reads 165 mg/dL on day 20 of her cycle might read 130 mg/dL on day 10. Both values deserve interpretation but should not both trigger the same clinical response without accounting for cycle timing.

Practical Timing Recommendation for Women

For the most reproducible lipid panel, women who are cycling regularly should schedule their fasting blood draw during the early-to-mid follicular phase (days 3 to 10 of the cycle, counting from day 1 of menstrual bleeding). This timing minimizes luteal-phase progesterone interference and captures the estradiol-replete state that reflects baseline hepatic lipid handling. Women on hormonal contraception with a 21/7 schedule should draw during the active-pill phase, when synthetic estrogen is present, for consistency.

Hormone Therapy and Fasting Triglycerides

Exogenous hormone use significantly alters fasting triglyceride levels, and the route of administration determines the direction and magnitude of that change.

Oral Estrogen Raises Triglycerides

Oral estradiol and conjugated equine estrogen (CEE) undergo first-pass hepatic metabolism, which substantially amplifies hepatic VLDL synthesis. The PEPI trial (N=875) found that oral CEE 0.625 mg/day raised fasting triglycerides by approximately 13.7% at 3 years compared to placebo [8]. Women who already have baseline fasting TG above 200 mg/dL should generally avoid oral estrogen and use transdermal or vaginal preparations instead.

Transdermal Estrogen is Triglyceride-Neutral

Transdermal estradiol patches or gels, dosed to achieve serum estradiol in the 50 to 100 pg/mL range, bypass hepatic first pass. The effect on fasting triglycerides is essentially neutral to slightly beneficial. A randomized crossover study by Vrablik et al. In Climacteric showed that transdermal estradiol 50 mcg/day produced no significant change in fasting triglycerides at 12 weeks, while the same women on oral estradiol 2 mg/day showed a 19% rise [9].

Testosterone Therapy in Women

Women on testosterone therapy (typically 5 to 20 mg/day via cream or gel for HSDD or hormonal optimization) show a dose-dependent reduction in fasting triglycerides similar to the male pattern. Higher doses, particularly those used by some clinicians to achieve supraphysiologic serum T, may lower HDL-C simultaneously, creating an unfavorable net lipid picture despite the TG reduction.

Progestins vs. Progesterone

Synthetic progestins, especially medroxyprogesterone acetate (MPA), have androgenic properties and may raise fasting triglycerides modestly. Micronized progesterone (Prometrium, 100 to 200 mg/day) has a neutral or mildly favorable lipid profile. The PEPI trial found that CEE plus MPA raised TG by 14%, while CEE plus micronized progesterone raised TG by only 11%, a smaller but still oral-estrogen-mediated increase [8].

Fasting Triglycerides in Metabolic Syndrome and MASLD

Elevated fasting triglycerides are one of the five defining criteria for metabolic syndrome and one of the most common lipid abnormalities in metabolic dysfunction-associated steatotic liver disease (MASLD).

Metabolic Syndrome Criterion

NCEP ATP-III requires three of five criteria for metabolic syndrome diagnosis, with fasting TG at or above 150 mg/dL as criterion number two [3]. The American Heart Association's 2009 update kept this threshold and added that drug treatment of elevated TG is an alternate indicator [10]. Approximately 31% of U.S. Adults meet at least one lipid criterion for metabolic syndrome based on NHANES 2017 to 2020 data.

MASLD and the TG Connection

In MASLD (formerly NAFLD), hypertriglyceridemia reflects excess hepatic de novo lipogenesis and impaired VLDL export. A 2023 Lancet Gastroenterology meta-analysis of 22 cohort studies found that fasting TG above 150 mg/dL increased MASLD incidence risk by 1.67-fold (95% CI 1.42 to 1.97) compared to TG below 100 mg/dL, after adjustment for BMI and fasting glucose [11]. Fasting TG is consequently a useful non-invasive screening signal for hepatic steatosis, particularly when combined with ALT and fasting glucose.

GLP-1 Receptor Agonists and TG Lowering

Semaglutide and tirzepatide both reduce fasting triglycerides substantially, an effect that goes beyond weight loss alone. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg/week reduced fasting triglycerides by 24.3% from baseline at 72 weeks, compared to 2.3% on placebo [12]. The mechanism includes suppression of hepatic de novo lipogenesis, reduction in dietary fat absorption rate, and direct hepatic GLP-1 receptor signaling.

GLP-1, Insulin Resistance, and the TG-Glucose Index

Fasting triglycerides are not just a lipid metric. They serve as a proxy for insulin resistance when combined with fasting glucose in the TG-glucose (TyG) index.

The TyG Index

The TyG index is calculated as: ln(fasting TG mg/dL × fasting glucose mg/dL / 2). A value above 8.5 correlates strongly with insulin resistance measured by euglycemic hyperinsulinemic clamp. A 2021 JAMA Network Open analysis of 6,273 participants found that TyG index predicted incident type 2 diabetes with an AUC of 0.77, outperforming fasting glucose alone (AUC 0.71) [13].

Sex-Specific TyG Thresholds

Because fasting TG baselines differ by sex and cycle phase, TyG thresholds may require sex-specific calibration. Women in the luteal phase of their cycle show TyG values roughly 0.15 to 0.20 points higher than the same women in the follicular phase, enough to cross an interpretation threshold if the clinician is unaware of cycle timing.

How to Interpret a Single Fasting Triglyceride Result

A single number rarely tells the full story. Context determines meaning.

Checklist Before Interpreting

1. Confirm the patient fasted 9 to 12 hours. If not, the result may be inflated by 20 to 70 mg/dL.
2. Ask about alcohol intake in the prior 48 hours. Even one drink the night before may raise the result by 30 to 50 mg/dL.
3. For women, note cycle day if cycling. Luteal-phase draws read higher by 15 to 25%.
4. Note exogenous hormone use and route. Oral estrogen raises TG; transdermal is neutral; testosterone lowers TG.
5. Consider recent carbohydrate binging. A 3-day very-high-carbohydrate intake can raise fasting TG by 50 to 100 mg/dL through upregulation of hepatic de novo lipogenesis.
6. Check thyroid function. Hypothyroidism raises VLDL secretion and is one of the most treatable causes of secondary hypertriglyceridemia.

Repeat Testing

If a first result falls between 150 and 499 mg/dL without an obvious dietary or hormonal explanation, repeat under optimal conditions (early follicular phase for women, morning, 10-hour fast, no alcohol for 48 hours) before initiating pharmacotherapy.

Lifestyle and Pharmacologic Levers for Triglyceride Reduction

Fasting triglycerides are among the most diet-responsive lipid parameters.

Dietary Changes

Reducing refined carbohydrate and added sugar intake produces the largest dietary effect on fasting TG. A meta-analysis of 89 randomized trials published in Annals of Internal Medicine found that a low-carbohydrate diet reduced fasting TG by a mean of 14.3 mg/dL more than a low-fat diet at 12 months [14]. Alcohol restriction is the single fastest intervention: cutting from moderate drinking to none reduces fasting TG by 20 to 50% within two to four weeks in patients with baseline values above 200 mg/dL.

Exercise

Aerobic exercise at 150 minutes per week reduces fasting TG by approximately 10 to 15% through increased skeletal muscle LPL activity. Resistance training adds a separate effect via improved insulin-stimulated glucose disposal, which reduces hepatic de novo lipogenesis substrate.

Pharmacotherapy Summary

• Fibrates (fenofibrate 145 mg/day): 30 to 50% TG reduction. First line for very high TG.
• EPA (icosapentaenoic acid, Vascepa 4 g/day): 20 to 30% TG reduction plus CV event reduction per REDUCE-IT [4].
• Niacin: 20 to 40% TG reduction but no CV benefit in AIM-HIGH or HPS2-THRIVE; rarely used now.
• GLP-1 receptor agonists (semaglutide 2.4 mg/week, tirzepatide 15 mg/week): 20 to 30% TG reduction with significant cardiometabolic co-benefits.
• Statins: 10 to 20% TG reduction as a secondary effect; primarily LDL-focused.